Akebia Therapeutics (AKBA) Set to Announce Earnings on Thursday

Akebia Therapeutics (NASDAQ:AKBA) is expected to be issuing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.0360) per share and revenue of $46.94 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Akebia Therapeutics (NASDAQ:AKBA) last announced its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.02. The firm had revenue of $49.13 million during the quarter, compared to analysts’ expectations of $48.85 million. Akebia Therapeutics had a negative return on equity of 88.88% and a negative net margin of 13.54%. On average, analysts expect Akebia Therapeutics to post ($0.14) EPS for the current fiscal year and ($0.27) EPS for the next fiscal year.

Akebia Therapeutics Stock Performance

NASDAQ:AKBA traded up $0.03 during mid-day trading on Tuesday, reaching $0.74. 1,638,793 shares of the stock were exchanged, compared to its average volume of 5,048,821. The company has a 50 day simple moving average of $0.84 and a 200-day simple moving average of $1.14. The stock has a market capitalization of $204.78 million, a P/E ratio of -6.69 and a beta of 0.18. The company has a quick ratio of 1.35, a current ratio of 1.43 and a debt-to-equity ratio of 0.99. Akebia Therapeutics has a 1 year low of $0.54 and a 1 year high of $2.15.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on AKBA. Weiss Ratings downgraded Akebia Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 2nd. Zacks Research raised shares of Akebia Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Leerink Partners cut shares of Akebia Therapeutics from an “outperform” rating to a “market perform” rating and set a $1.00 target price on the stock. in a report on Friday, August 7th. HC Wainwright reiterated a “buy” rating on shares of Akebia Therapeutics in a research report on Thursday, August 6th. Finally, BTIG Research reiterated a “buy” rating and set a $4.00 price target on shares of Akebia Therapeutics in a research note on Tuesday, September 15th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $3.90.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for patients with kidney disease and related conditions. The company’s primary areas of interest include anemia associated with chronic kidney disease (CKD), iron deficiency, and disorders involving mineral metabolism.

Akebia’s key product is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to stimulate the body’s natural production of erythropoietin and support red blood cell formation.